Spiber
Japanese biotech that ferments spider-silk-like protein fibers for apparel and cars.
On the record
Checkpoint: CRANE's first independent post-restructuring financial disclosure
The call
Spiber Inc. is being liquidated after failing to pay about 40 billion yen in debt, with its business handed to an unproven successor called CRANE.
Spiber made lab-grown spider silk and other engineered materials for clothing and industry. The company ran out of money in early 2026, loaded with about $300 million in debt it could not pay back, so it handed nearly its entire business to a brand-new company called CRANE on March 31, 2026, and is now being shut down. The real question is whether CRANE can survive on its own: does it still have paying customers, cash in the bank, and employees willing to stay, or did everyone leave when the old company failed? A competing company called Bolt Threads is also in serious trouble at the same time, which means there is no healthy rival to learn from. Watch for CRANE's first honest financial report (how many workers, who is buying, how much money left) and whether big fashion or industry partners sign real new deals with the new company or decide to walk away. Also watch what happens to Spiber's US operations, which were not part of the transfer to CRANE, because that will show how badly damaged the whole thing really is.
Why
01
AI pressure: None apparent. AI is not what broke Spiber. Unpaid debt and US production cost overruns did. Could AI do the core job? Unlikely.
02
Bigger players: None apparent. No big rival pushed Spiber out. It ran out of cash servicing about 40 billion yen in debt and collapsed on its own. Could a giant copy it? Probably.
03
What protects it. Brand ties to Toyota, Goldwin and Kering could carry into CRANE if the new entity proves it can actually deliver at cost.
What would change this call
CRANE releases its first independent financial disclosure (Q3-Q4 2026). Shows whether the successor entity has viable revenue, cash, and retained staff.
Toyota, Kering, or Goldwin sign new priced offtake contracts with CRANE, or decline to. Reveals whether marquee brand partners still trust the post-restructuring business.
Bolt Threads discloses further distress or files for bankruptcy protection. Would confirm a sector-wide capital crisis among engineered-silk biomaterial makers.
Toyota, Kering, or Goldwin sign new priced offtake contracts with CRANE, or decline to. Reveals whether marquee brand partners still trust the post-restructuring business.
Bolt Threads discloses further distress or files for bankruptcy protection. Would confirm a sector-wide capital crisis among engineered-silk biomaterial makers.
Key numbers
- ¥40B in debt Spiber could not repay
- ¥28B loss from US plant cost overruns
- $312M Carlyle round valued it at $1.22B
Named risks
- Original Spiber Inc. entity is being liquidated after defaulting on ~¥40B debt.
- Successor entity CRANE has no verified post-restructuring financials, customers, or headcount.
- US operations were excluded from the March 2026 business transfer with unresolved fate.
- Key investor Cool Japan Fund faces possible merger/abolition amid ¥54B losses.
- Entire synthetic-biomaterials category under capital retrenchment as peer Bolt Threads also faces going-concern doubt.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Bolt Threads | contesting | Both distressed simultaneously; Bolt Threads delisted from Nasdaq to OTC Pink around January 2026 with going-concern doubt. |
| AMSilk | contesting | Named as closest direct competitor in recombinant spider-silk biomaterials as of March 2024, no share-loss evidence found. |
| MycoWorks | gaining on | Operating a commercial mycelium-leather plant since 2023 with longer-horizon capital, per May 2026 industry commentary. |
| Kraig Biocraft Laboratories | contesting | Listed as a peer OTC-traded competitor (KBLB) in synthetic spider-silk materials market analysis, March 2024. |
Questions people ask
- Is Spiber profitable in 2026?
- No. Spiber Inc. could not service roughly ¥40 billion in debt by end of 2025 and entered an out-of-court workout with creditors writing off obligations, transferring its business to a new entity, CRANE, on March 31, 2026.
- Did Spiber go bankrupt?
- Spiber underwent a private debt restructuring rather than formal bankruptcy: unable to service ~¥40B in debt by December 2025, it transferred substantially all operations to successor entity CRANE on March 31, 2026, and the original corporate entity is expected to be liquidated.
- Who owns Spiber now?
- As of April 1, 2026, Spiber's business is run by CRANE, a new entity registered about two months earlier in Tsuruoka that took over operations (excluding US business) after the original Spiber Inc. defaulted on roughly ¥40 billion in debt.
- Who is Spiber's biggest competitor?
- Bolt Threads is Spiber's closest peer in engineered biomaterials, but it is also in crisis: it had only $3.5 million cash at 2024 year-end, ~$4.5M preliminary 2025 revenue, and was delisted from Nasdaq to OTC Pink around January 2026.
- Can AI replace Spiber's fermentation technology?
- Not directly. Spiber's core value is wet-lab fermentation manufacturing and physical plants (e.g., Thailand, operational since 2022), which AI cannot replicate, though generative protein-design tools could gradually erode its R&D differentiation over time.
- What caused Spiber's financial collapse?
- Spiber recorded an extraordinary loss of roughly ¥28 billion in 2024 tied to cost overruns on US production infrastructure, reportedly about 3x initial projections, which contributed to it being unable to service ~¥40B in debt by end of 2025.
Timeline
- 2026-06-24Cool Japan Fund, a Spiber investor, faces merger/abolition after ¥54B cumulative losses
- 2026-04-01New entity CRANE becomes operational, taking over Spiber's business under the Spiber brand
- 2026-03-31Spiber transfers substantially all business to CRANE; original entity to be liquidated
- 2026-01Peer Bolt Threads delisted from Nasdaq, moves to OTC Pink under ticker BSLK
- 2025-12Spiber cannot service ~¥40B in debt, enters out-of-court creditor workout
- 2024-09Spiber valuation reported at ¥169.5 billion
- 2024-04-12Spiber raises over ¥10 billion for mass production and sales initiatives
- 2024Spiber records ¥28 billion extraordinary loss from US production cost overruns
- 2022Spiber's Thailand mass-production fermentation plant becomes operational
- 2021-09-08Carlyle-led $312M round values Spiber at ~$1.22 billion
Revision history
29 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Write It Off and Try Again (2026-04-01)
- Carlyle leads $312 million funding round for Japanese unicorn Spiber (2021-09-08)
- Spiber Stock Price, Funding, Valuation, Revenue & Financial Statements (2024-04-11)
- Can Spiber make spider silk-like materials a reality? (2021-04-11)
- Spiber 2026 Company Profile
- Between 'Dream Fibers' and Down-to-Earth Textiles｜ISILK (2026-03-26)
- Spiber Inc snags ¥10bn to accelerate mass production of eco-fibres
- Global Synthetic Spider Silk Market Trends Analysis (2024-03-25)
- What killed Mylo, and what bio-materials founders should actually learn from it (2026-05-20)
- Cool Japan Fund faces possible merger, cuts after losses hit $334 million (2026-06-24)
- Spiber Inc.
- Spiber Technologies 2026 Company Profile